Abstract
Introduction and objectives: Treatment of Retinopathy of Prematurity (ROP) is revolutionized by the use of Anti-Vascular Endothelial Growth Factor agents over the last decade. This study describes the results of the treatment in the newest paediatric ophthalmology unit in Sri Lanka- Teaching hospital, Jaffna. Methods: Retrospective analysis of the ROP screening and treatment data at the paediatric ophthalmology unit at teaching hospital was carried out. All the screening and treatment sessions were carried out under topical anaesthesia. Out of the 118 babies who underwent screening examinations, 12 babies had severe ROP requiring treatment with intravitreal injection of Bevacizumab. In conclusion intravitreal injection of Bevacizumab is very successful in managing severe Zone 1 and Zone 2 ROP although prolong follow up is mandatory to detect recurrences of ROP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
